Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-12-16
2009-08-11
Blanchard, David J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S001490, C424S155100, C435S320100, C435S338000, C435S069100, C536S023530
Reexamination Certificate
active
07572444
ABSTRACT:
Binding proteins, such as fully human monoclonal antibodies and fragments thereof, directed to the antigen Matriptase and uses of such binding proteins are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising heavy and light chain immunoglobulin molecules capable of binding to Matriptase are also disclosed. The invention also discloses cell lines expressing such immunoglobulin molecules and monoclonal antibodies to Matriptase. The antibodies can be used to detect, prevent, and treat diseases such as cancer.
REFERENCES:
patent: 6677377 (2004-01-01), Lin et al.
patent: 7022821 (2006-04-01), O'Brien et al.
patent: WO 01/29056 (2001-04-01), None
Search output from ATCC website for sc95/96 and sc136 (pp. 1-2).
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
Benaud et al. (Eur. J. Biochem. 268:1439-1447 (2001).
Green (J. Immunol. Methods 231:11-23 (1999).
Sun (Breast Cancer Research Program grant award-year 2001 (Abstract of Grant Award (pp. 1-3); Sun II).
Lin, et al., “Characterization of a Novel, Membrane-bound, 80-kDa Matrix-degrading Protease from Human Breast Cancer Cells,” Journal of Biological Chemistry, vol. 272, No. 14, pp. 9147-9152 (Apr. 4, 1997).
Sun, et al., “Potent and Selective Inhibition of Membrane-Type Serine Protease 1 by Human Single-Chain Antibodies,”Biochemistry2003, 42, pp. 892-900.
Foltz, Ian et al., “Generation of a Fully Human High Affinity Neutralizing Antibody Against MT-SP1/Matriptase and Its Potential Role for the Treatment of B Cell Lymphoma,” Blood, vol. 106, 2005, p. 284B.
Lin, Chen-Yong et al., “Purification and Characterization of a Complex Containing Matriptase and a Kunitz-type Serine Protease Inhibitor from Human Milk,” The Journal of Biological Chemistry, vol. 274, No. 26, Jun. 25, 1999, pp. 18237-18242.
Takeuchi, Toshihiko et al., “Cellular Localization of Membrane-type Serine Protease 1 and Identification of Protease-activated Receptor-2 and Single-chain Urokinase-type Plasminogen Activator as Substrates,” The Journal of Biological Chemistry, vol. 275, No. 34, Aug. 25, 2000, pp. 26333-26342.
Takeuchi, Toshihiko et al., “Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue,” Proc. Natl. Acad. Sci., vol. 96, Sep. 1999, pp. 11054-11061.
International Search Report dated Jul. 3, 2006 for International Application No. PCT/US2005/045755.
Lee et al., Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease,J Biol Chem. (2000);275(47):36720-5.
ROC (Taiwan) Search Report for Patent Application No. 094144958.
ROC (Taiwan) Search Report for Patent Application No. 094144958, Jan. 31, 2008.
Chen Francine
Foltz Ian
Godfrey Wayne R.
Kang Jaspal Singh
Keyt Bruce A.
Amgen Fremont Inc.
Blanchard David J.
Bristol Lynn
Dendreon Corporation
Knobbe Martens Olson & Bear LLP
LandOfFree
Binding proteins specific for human matriptase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Binding proteins specific for human matriptase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Binding proteins specific for human matriptase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4062494